Alpha Articles
Alimta: first effective mesothelioma drug
27 May 2002
Tokyo pharma stocks - week to May 13
20 May 2002
Mitsubishi expects spiralling profits
13 May 2002
Tokyo pharma stocks - week to May 6
13 May 2002
Lilly starts pivotal trial of antisense NSCLC drug
29 April 2002
Lilly, Ligand extend R&D alliance in diabetes etc
22 April 2002
Infliximab shows efficacy in spondylitis
15 April 2002
Remicade gains FDA priority for CD
8 April 2002
CTI gets European OK for Trisenox in APL
18 March 2002
Hybridon starts Campto/antisense trial
11 March 2002
SciClone: positive Ph III data on HBV agent
11 March 2002
Alpha Innotech raises $8 million.
21 January 2002
Immerge reports pig cloning advance
14 January 2002
Maxim initiates Ceplene Phase II trials
7 January 2002
GSK's dutasteride for BPH cleared in USA
7 January 2002
Elan and Biogen initiate Phase III trial for Antegren
7 January 2002
Novartis and Kissei develop new class of glaucoma treatment
7 January 2002
GSK's dutasteride for BPH cleared in USA
28 December 2001
Elan and Biogen initiate Phase III trial for Antegren
20 December 2001
Maxim initiates Ceplene Phase II trials
19 December 2001
Novartis and Kissei develop new class of glaucoma treatment
18 December 2001
Genzyme to acquire Pharming's Pompe disease portfolio
10 December 2001
Novartis files for GIST indication for Glivec in EU
6 December 2001
PDL to test Zenapax in asthma patients
28 November 2001
Bristol-Myers Squibb highlights five key products at R&D day
15 November 2001
Novo Nordisk starts Ph II on DRF-2725
8 November 2001
Tokyo pharma stocks - week to November 5
7 November 2001
Viragen signs major deal in Taiwan
2 November 2001
Bayer unveils new preclinical drug candidates
26 October 2001
Losses deepen at BioMarin
26 October 2001
Malaysian marketing deal for GeneMedix
17 October 2001
Baxter boosts oncology business with Epoetin Omega buy
17 October 2001
BioNative of Sweden bought by Viragen
3 October 2001
Skepticism over French 2002 health care spending budget
25 September 2001
Elan and Biogen's Antegren to start Phase III trials in MS
17 September 2001
Novo to move diabetes drug into Phase III
13 September 2001
Xtrana gains UK, Ireland distributor
13 September 2001
Japan pharma stocks, week to Sept 10
11 September 2001
SciClone makes progress with Zadaxin in Japan
23 August 2001
GeneMedix highlights six-month progress
22 August 2001
TNF-alpha inhibitor sales forecast to soar
22 August 2001
Nereus Pharmaceuticals raises $23.6 million
30 July 2001
Pharming looks to raise more funds
24 July 2001
Bayer backs PPL share issue with L15 million
13 July 2001
Japan pharma stocks - week to July 9
11 July 2001
Japan pharma stock market, week to June 25
27 June 2001
UK approves Viragen's Omniferon trials
22 June 2001
BioPartners signs pact with Cambridge Labs
22 June 2001
TKT evaluates Replagel in renal transplant patients
14 June 2001
Celgene drug promises activity in solid tumors
8 June 2001
Ph I results with Palatin's ED drug PT-141
7 June 2001
Eprex lowers cancer patients' transfusion rates
6 June 2001
Elan/Biogen's Antegren promising in Crohn's
31 May 2001
Cardura safety mulled by FDA panel
30 May 2001
Bayer/PPL's rec-AAT gets orphan status in EU
30 May 2001
Novartis gets diabetes rights from Dr Reddy
30 May 2001
B-MS returns rights to cancer vaccines
24 May 2001
BioMarin Pharma gets $45 million boost
18 May 2001
MPS-I patients benefit from Aldurazyme
17 May 2001
Tokyo pharma stock market - week to April 23
25 April 2001
ISIS' anti-TNF antisense drug in Phase I
11 April 2001
Nycomed licenses Biopartners' portfolio
29 March 2001
HGS starts trials of Albuferon in HCV
26 March 2001
Novartis's Visudyne use extended in EU
26 March 2001
BioMarin Aldurazyme Ph II enrollment
2 March 2001
Stock Commentary - Tokyo
22 February 2001
BioMarin gets boost as Acqua Wellington puts in $50 million
2 February 2001
Xatral OD filed for US marketing approval
23 January 2001
Pharming leaps on Pompe's drug news
15 January 2001
Genzyme hit by delay to Fabrazyme; opportunity for TKT?
2 January 2001
BASF sells pharma business to Abbott Labs for $6.9 billion in cash
15 December 2000
Novartis' CML drug Glivec dominates ASH conference
5 December 2000
Merck to seek Vioxx OK for rheumatoid arthritis
24 November 2000
BASF excited about prospects for D2E7, as rumor mill talks of pharma
15 November 2000
Karo Bio and Merck & Co extend deal
2 November 2000
Schering licenses Population Council's MENT
2 November 2000
Stock Commentary - Tokyo
2 November 2000
Second BioMarin enzyme enters trials
16 October 2000
First clinical data for Pompe disease drug
9 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
EMEA adopts orphan drug designations
22 September 2000
Pharming granted US patent on human alpha glucosidase
13 September 2000
Enzon files suit against Roche over Pegasys
7 September 2000
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
